JP2007500145A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500145A5 JP2007500145A5 JP2006521446A JP2006521446A JP2007500145A5 JP 2007500145 A5 JP2007500145 A5 JP 2007500145A5 JP 2006521446 A JP2006521446 A JP 2006521446A JP 2006521446 A JP2006521446 A JP 2006521446A JP 2007500145 A5 JP2007500145 A5 JP 2007500145A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- cooh
- coo
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 104
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 46
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- -1 -C (O) O-alkyl Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000006419 fluorocyclopropyl group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 26
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 18
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims 18
- 239000000556 agonist Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 9
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 150000004885 piperazines Chemical class 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 229940086609 Lipase inhibitor Drugs 0.000 claims 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102000004146 ATP citrate synthases Human genes 0.000 claims 1
- 108090000662 ATP citrate synthases Proteins 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000013585 Bombesin Human genes 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 102000019432 Galanin Human genes 0.000 claims 1
- 101800002068 Galanin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 1
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 229940122014 Lyase inhibitor Drugs 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 claims 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 claims 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 claims 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 claims 1
- 102000005630 Urocortins Human genes 0.000 claims 1
- 108010059705 Urocortins Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 239000003392 amylase inhibitor Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 208000026099 carbohydrate metabolic disease Diseases 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002697 lyase inhibitor Substances 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 1
- 239000002658 neuropeptide Y receptor agonist Substances 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 230000000862 serotonergic effect Effects 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 239000000777 urocortin Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- AOAGGWLQIILIIV-UHFFFAOYSA-N 2-bromo-1-[4-(trifluoromethoxy)phenyl]ethanone Chemical compound FC(F)(F)OC1=CC=C(C(=O)CBr)C=C1 AOAGGWLQIILIIV-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10334309A DE10334309A1 (de) | 2003-07-28 | 2003-07-28 | Substituierte Thiazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| PCT/EP2004/007847 WO2005012295A1 (de) | 2003-07-28 | 2004-07-15 | Substituierte thiazol-benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500145A JP2007500145A (ja) | 2007-01-11 |
| JP2007500145A5 true JP2007500145A5 (enExample) | 2007-08-30 |
Family
ID=34111694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521446A Abandoned JP2007500145A (ja) | 2003-07-28 | 2004-07-15 | 置換チアゾール−ベンゾイソチアゾールジオキシド誘導体、それらの製造方法、およびそれらの使用 |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004026532A1 (de) * | 2004-05-29 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Oxazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| CN101415683B (zh) | 2006-03-31 | 2013-07-17 | 诺瓦提斯公司 | 新化合物 |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2025017207A1 (en) * | 2023-07-20 | 2025-01-23 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Inhibitors of smndc1 and their therapeutic use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539584A (en) * | 1967-11-14 | 1970-11-10 | Colgate Palmolive Co | 5-substituted-2,1-benzisothiazolines |
| JPH04128276A (ja) * | 1990-09-19 | 1992-04-28 | Pfizer Pharmaceut Co Ltd | アミノベンゾサルタム誘導体およびその用途 |
| RU2164226C2 (ru) * | 1995-06-02 | 2001-03-20 | Санофи-Синтелябо | Производные 5-(гидроксиметил)-оксазолидин-2-она, способы их получения, лекарство и фармацевтический состав |
| CO5190696A1 (es) * | 1999-06-16 | 2002-08-29 | Smithkline Beecham Corp | Antagonistas de los receptores il-8 |
| DE10038709A1 (de) * | 2000-08-09 | 2002-02-28 | Aventis Pharma Gmbh | Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen |
-
2003
- 2003-07-28 DE DE10334309A patent/DE10334309A1/de not_active Withdrawn
-
2004
- 2004-06-14 JO JO200481A patent/JO2449B1/en active
- 2004-07-13 PE PE2004000664A patent/PE20050326A1/es not_active Application Discontinuation
- 2004-07-15 AT AT04741034T patent/ATE346065T1/de not_active IP Right Cessation
- 2004-07-15 WO PCT/EP2004/007847 patent/WO2005012295A1/de not_active Ceased
- 2004-07-15 PA PA20048607201A patent/PA8607201A1/es unknown
- 2004-07-15 BR BRPI0412997-0A patent/BRPI0412997A/pt not_active IP Right Cessation
- 2004-07-15 SI SI200430126T patent/SI1651644T1/sl unknown
- 2004-07-15 CN CNB2004800220877A patent/CN100413862C/zh not_active Expired - Fee Related
- 2004-07-15 EP EP04741034A patent/EP1651644B1/de not_active Expired - Lifetime
- 2004-07-15 RS YUP-2006/0015A patent/RS20060015A/sr unknown
- 2004-07-15 PT PT04741034T patent/PT1651644E/pt unknown
- 2004-07-15 DE DE502004002117T patent/DE502004002117D1/de not_active Expired - Lifetime
- 2004-07-15 UA UAA200602134A patent/UA83057C2/ru unknown
- 2004-07-15 AU AU2004261370A patent/AU2004261370B2/en not_active Ceased
- 2004-07-15 OA OA1200600026A patent/OA13198A/en unknown
- 2004-07-15 ES ES04741034T patent/ES2276319T3/es not_active Expired - Lifetime
- 2004-07-15 NZ NZ544975A patent/NZ544975A/en unknown
- 2004-07-15 DK DK04741034T patent/DK1651644T3/da active
- 2004-07-15 RU RU2006106231/04A patent/RU2350613C2/ru not_active IP Right Cessation
- 2004-07-15 CA CA002533673A patent/CA2533673A1/en not_active Abandoned
- 2004-07-15 JP JP2006521446A patent/JP2007500145A/ja not_active Abandoned
- 2004-07-15 KR KR1020067001721A patent/KR20060052886A/ko not_active Ceased
- 2004-07-15 PL PL04741034T patent/PL1651644T3/pl unknown
- 2004-07-23 GT GT200400146A patent/GT200400146A/es unknown
- 2004-07-26 TW TW093122232A patent/TW200524923A/zh unknown
- 2004-07-26 AR ARP040102644A patent/AR045113A1/es not_active Application Discontinuation
- 2004-07-27 MY MYPI20043005A patent/MY141197A/en unknown
- 2004-07-28 UY UY28443A patent/UY28443A1/es unknown
- 2004-10-11 SA SA04250332A patent/SA04250332B1/ar unknown
-
2005
- 2005-12-21 ZA ZA200510378A patent/ZA200510378B/xx unknown
-
2006
- 2006-01-18 CR CR8202A patent/CR8202A/es not_active Application Discontinuation
- 2006-01-22 IL IL173289A patent/IL173289A0/en unknown
- 2006-01-26 EC EC2006006326A patent/ECSP066326A/es unknown
- 2006-01-26 MA MA28753A patent/MA27932A1/fr unknown
- 2006-01-27 TN TNP2006000030A patent/TNSN06030A1/en unknown
- 2006-02-24 NO NO20060908A patent/NO20060908L/no not_active Application Discontinuation
-
2007
- 2007-01-29 CY CY20071100112T patent/CY1105962T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500145A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| von Geldern et al. | Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity | |
| RU2006106231A (ru) | Замещенные производные диоксида тиазолбензоизотиазола, способ их получения и их применение | |
| CN101370799B (zh) | 作为mdm2抑制剂的顺-4,5-二芳基-2-杂环-咪唑啉 | |
| JP2006502247A5 (enExample) | ||
| CN1152870A (zh) | 杂环化合物作为多巴胺d3配位体的用途 | |
| JP2008513498A5 (enExample) | ||
| CN108558831B (zh) | 取代吡咯-4-烷基胺类化合物及其用途 | |
| JP2007523155A5 (enExample) | ||
| RU2702644C2 (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
| HRP20120829T1 (hr) | Karboksilne kiseline supstituirane fenilaminobenzoksazolom, postupak njihovog dobivanja i njihova upotreba kao medikamenata | |
| KR20090101905A (ko) | 인돌-４-일-피리미디닐-일-아민 유도체 및 사이클린 의존성 키나제 억제제로서의 그의 용도 | |
| MX2010012699A (es) | Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina. | |
| WO2013185507A1 (zh) | 苯并噻嗪-4-酮衍生物及其制备方法和用途 | |
| CN1165522C (zh) | 缓激肽受体拮抗剂 | |
| RU2006147245A (ru) | Замещенные производные оксазол-бензоизотиазолдиоксида, способ их получения и их применения | |
| CN100349893C (zh) | 用作磷酸二酯酶抑制剂的取代2,4－二氢－吡咯并[3,4－b]喹啉－9－酮衍生物 | |
| MX2015002310A (es) | Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer. | |
| WO2004080943A1 (ja) | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 | |
| CN101484159A (zh) | 通过使用加兰肽-3受体拮抗剂调节轴突外生长的方法 | |
| TWI254706B (en) | Cyclic amine compounds and pharmaceutical composition containing the same | |
| US6924295B2 (en) | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | |
| CN1434816A (zh) | 新化合物 | |
| EP2643307B1 (fr) | Derives de nitrobenzothiazoles et leur utilisation pour le traitment de la tubercolose |